Teleflex Incorporated TFX
Teleflex Incorporated (NYSE: TFX) is a medical device company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Nov 5, 2026submitted Teleflex received FDA Breakthrough Device Designation for Freesolve™ RMS in percutaneous coronary intervention (PCI).
Received FDA Breakthrough Device Designation (BDD) for FreesolveTM RMS in percutaneous coronary intervention (PCI), building on the 2024 BDD for below-the-knee (BTK) treatment of chronic limb-ischemia
Filing - Nov 5, 2026completed enrollment BIOMAG™-LL clinical study completed enrollment of 102 patients across 14 European centers.
Completed enrollment of 102 patients across 14 European centers evaluating 35 mm and 40 mm FreesolveTM RMS lengths in de novo coronary lesions up to 38 mm
Filing - Nov 5, 2026started BIOMAG™-III U.S. pivotal trial underway to support a future PMA submission.
BIOMAGTM-III: U.S. pivotal trial underway to support a future Premarket Approval (PMA) submission
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.